LIPK Human Pre-designed siRNA Set A contains three designed siRNAs for LIPK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LIPM Human Pre-designed siRNA Set A contains three designed siRNAs for LIPM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LIPN Human Pre-designed siRNA Set A contains three designed siRNAs for LIPN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lipoxin A4 methyl ester is a stable synthetic analog of lipoxin with anti-inflammatory properties that can be extracted from arachidonic acid[1].

Lipoxin A5 is an eicosapentaenoic acid derived from pig white blood cells. Lipoxin A5 slowly contracted the guinea pig lung parenchymal strips with a contractile force similar to that of LXA4 and LXB4.2, but LXA5 did not have the vasodilating effect on the aortic smooth muscle shown by LXA4 and LXB4.2[1][2].

Lipoxin B4 (LXB4) is a structurally distinct product of arachidonic acid metabolism. Lipoxin B4 reduces leukocyte infiltration and mucus secretion in the nasal mucosa and decreases mast cell and eosinophil degranulation in the upper airway. Lipoxin B4 decreases airway inflammation, mucus metaplasia and hyper- responsiveness in the lower airway. Lipoxin B4 shows mucosal protective actions […]

LIPT1 Human Pre-designed siRNA Set A contains three designed siRNAs for LIPT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Liraglutide-13C6,15N (TFA)is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus[1].

LIT-927 is a locally and orally active CXCL12 neutraligand with anti-inflammatory effect, with a Ki of 267 nM for CXCL12 binding to its specific receptor CXCR4[1] .

LIT-927 is a locally and orally active CXCL12 neutraligand with anti-inflammatory effect, with a Ki of 267 nM for CXCL12 binding to its specific receptor CXCR4[1] .

LIT-927 is a locally and orally active CXCL12 neutraligand with anti-inflammatory effect, with a Ki of 267 nM for CXCL12 binding to its specific receptor CXCR4[1] .

LIT-927 is a locally and orally active CXCL12 neutraligand with anti-inflammatory effect, with a Ki of 267 nM for CXCL12 binding to its specific receptor CXCR4[1] .

LIT-927 is a locally and orally active CXCL12 neutraligand with anti-inflammatory effect, with a Ki of 267 nM for CXCL12 binding to its specific receptor CXCR4[1] .

LIT-927 is a locally and orally active CXCL12 neutraligand with anti-inflammatory effect, with a Ki of 267 nM for CXCL12 binding to its specific receptor CXCR4[1] .

LITAF Human Pre-designed siRNA Set A contains three designed siRNAs for LITAF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lithium carbonate (Carbolithium) is a biochemical reagent that can be used as a biological material or organic compound for life science related research[1].

Lithium chloride, 99% (LiCl, Premium grade) is a biochemical reagent that can be used as a biological material or organic compound for life science related research[1].

LIX1 Human Pre-designed siRNA Set A contains three designed siRNAs for LIX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LIX1L Human Pre-designed siRNA Set A contains three designed siRNAs for LIX1L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LL-37-Cys is a LL-37 (HY-P1222) with a C-terminal reduced cystein residue[1][.

LLGL1 Human Pre-designed siRNA Set A contains three designed siRNAs for LLGL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LLGL2 Human Pre-designed siRNA Set A contains three designed siRNAs for LLGL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LLK203 is a potent USP2/USP8 dual-target inhibitor with IC50s of 0.89 μM and 0.52 μM, respectively. LLK203 leads a degradation of ERα and induces apoptosis of breast cancer MCF-7 cells. LLK203 demonstrates antitumor activities against the 4T1 tumor mice model[1].

LLPH Human Pre-designed siRNA Set A contains three designed siRNAs for LLPH gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LM-021 is a coumarin-chalcone derivative with anti-aggregatory, antioxidant, neuroprotective and anti-inflammatory properties which suppresses nitric oxide (NO), IL-1β, IL-6, TNF-α production, CD68 antigen (CD68) and histocompatibility-2 (MHCII) expression. LM-021 also attenuates the increase of caspase 1 activity, lactate dehydrogenase release and ROS level. LM-021 can be used for neurological research[1].

LM11 is an inhibitor of transglutaminase 2 (TG2) with an activity of killing glioblastoma cells by maintaining TG2 in a cytotoxic conformational state[1].

LMAN1 Human Pre-designed siRNA Set A contains three designed siRNAs for LMAN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMAN2 Human Pre-designed siRNA Set A contains three designed siRNAs for LMAN2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMAN2L Human Pre-designed siRNA Set A contains three designed siRNAs for LMAN2L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMBR1 Human Pre-designed siRNA Set A contains three designed siRNAs for LMBR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMBR1L Human Pre-designed siRNA Set A contains three designed siRNAs for LMBR1L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMBRD1 Human Pre-designed siRNA Set A contains three designed siRNAs for LMBRD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMBRD2 Human Pre-designed siRNA Set A contains three designed siRNAs for LMBRD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMCD1 Human Pre-designed siRNA Set A contains three designed siRNAs for LMCD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMF1 Human Pre-designed siRNA Set A contains three designed siRNAs for LMF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMF2 Human Pre-designed siRNA Set A contains three designed siRNAs for LMF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMLN Human Pre-designed siRNA Set A contains three designed siRNAs for LMLN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMNA Human Pre-designed siRNA Set A contains three designed siRNAs for LMNA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LMNB1 Human Pre-designed siRNA Set A contains three designed siRNAs for LMNB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.